Titel: Personalized Medicine Europe: Health, Genes & Society
Termin:
19.6.2005
Veranstaltungsort:
Tel-Aviv University
Tel-Aviv, Israel
Weitere Informationen:
http://www.functionalgenomics.org.uk/sections/activitites/2005/Livshit ...
Changes will be taking place in the way medicine is practiced and therapeutics are being prescribed. This will be true not only for treating diagnosed diseases, but increasingly so for preventive medicine: lowering risks for genetically susceptible individuals for a multitude of chronic diseases, such as, type II diabetes, CVD, Alzheimer's and autoimmune diseases, and affective disorders.
Personalized medicine, the foremost practical outcome of the Human Genome Project, should allow patients to be diagnosed at early stages of disease, likely before too much tissue damage has accumulated, and treated with the most fitting medicines, according to their genotypes.
Advances have already been incorporated into the clinical setting in recent years, most notably by individualising treatment decisions in oncology, in particular for leukemia, and for breast, colon, and pancreatic cancers.
The advent of certain other aspects of personalized medicine, such as the tailoring of the most effective anti-depressant drugs, may be just around the corner. Indeed, the practice of medicine is certain to be transformed within two to four decades by imminent genomic information technologies.
All these changes will require new ways of thinking about health and disease, with a corresponding reshaping of our diagnostic and disease terminology, as well as more effective programs for preventive medicine.
The ethical and societal aspects of genotype-based drug treatments remain highly debated. History has taught us that new technologies reshape human society in unpredictable manners. Just consider the societal changes conveyed during the past two hundred years by the advent of electricity, aviation, telecommunications, and recently, the internet.
Consider the transformation in medicine conveyed during the 20th century by X-ray and more advanced imaging technologies, culminating with functional MRI (fMRI) being established as a novel discipline. Would anyone in his senses, 50 years ago, imagine that we should have the capacity to "capture" the brain activity so clearly?
Likewise, it is not simple to extrapolate developments that will be taking place during the 21st century with the advent of yet more powerful genotyping technologies, possibly allowing full genome sequencing for the individual patient in matter of few hours and at a cost similar to MRI scan.
We hope that this workshop will form a stage for discussing the impact of pharmacogenomics and personalized medicine on biomedical and societal developments. The workshop will focus on the clinical practice of health care delivery, taking into account regulatory and policy aspects and bioethics.
Personalized Medicine Europe: Health, Genes & Society will provide an integrated forum for exchanging views between academic and clinical researchers, representatives of pharmaceutical and biotech companies, and healthcare management organizations. The workshop should assist these parties to discuss ways for reshaping the future of medicine by providing a platform for expert reports and panel discussions.
Kontakt:
Mr. Gregory Livshits
Mr. David Gurwitz
gregl@post.tau.ac.il; gurwitz@post.tau.ac.il
Veranstalter: Tel-Aviv University / Israel
Schlagworte: Genetische Tests/Beratung, Genforschung/-technik, Genomanalyse, Gentherapie, Gesundheitswesen